Bridging the gap between a TB drug and its target.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 22956196.
- Also identified by DOI 10.1126/scitranslmed.3004816.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A promising new TB drug cocrystallized with its mycobacterial target provides a platform for structure-based design that will improve TB drug development (Neres et al.).
Medical subject headings
- Antitubercular Agents
- Microbial Viability
- Mycobacterium tuberculosis
- Thiazines